CIK 0001714899 · Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 463872213
- Phone
- (650) 866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $363,678
- in 3 filings, $327K under 10b5-1 plans
Net −$363,678. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 8 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-12-12 | Flagship Ventures Fund V, L.P. 10% owner | Conversion · Series B-1 Preferred Stock | −156,250 | 0 | ||
| 2017-12-12 | ARCH Venture Fund VIII, L.P. 10% owner | Conversion | +10,756,249 | 11,068,749 | ||
| 2017-12-12 | ARCH Venture Fund VIII, L.P. 10% owner | Conversion · Series A-1 Preferred Stock | −10,068,749 | 0 | ||
| 2017-12-12 | ARCH Venture Fund VIII, L.P. 10% owner | Conversion · Series A-2 Preferred Stock | −375,000 | 0 | ||
| 2017-12-12 | ARCH Venture Fund VIII, L.P. 10% owner | Conversion · Series B-1 Preferred Stock | −312,500 | 0 | ||
| 2017-12-12 | Tessier-Lavigne Marc Director | Conversion | +25,000 | 3,139,043 | ||
| 2017-12-12 | Tessier-Lavigne Marc Director | Conversion · Series A-1 Preferred Stock | −25,000 | 0 | ||
| 2017-12-12 | Schenkein David P Director | Conversion | +105,225 | 105,225 | ||
| 2017-12-12 | Schenkein David P Director | Conversion | +19,774 | 19,774 | ||
| 2017-12-12 | Schenkein David P Director | Conversion | +105,225 | 105,225 | ||
| 2017-12-12 | Schenkein David P Director | Conversion | +19,774 | 19,774 | ||
| 2017-12-12 | Schenkein David P Director | Conversion · Series A-1 Preferred Stock | −105,225 | 0 | ||
| 2017-12-12 | Schenkein David P Director | Conversion · Series A-1 Preferred Stock | −19,774 | 0 | ||
| 2017-12-12 | Schenkein David P Director | Conversion · Series A-1 Preferred Stock | −105,225 | 0 | ||
| 2017-12-12 | Schenkein David P Director | Conversion · Series A-1 Preferred Stock | −19,774 | 0 | ||
| 2017-12-12 | SATO VICKI L Director | Conversion | +62,500 | 137,500 | ||
| 2017-12-12 | SATO VICKI L Director | Conversion · Series A-1 Preferred Stock | −62,500 | 0 | ||
| 2017-12-12 | NELSEN ROBERT Director | Conversion | +10,756,249 | 11,068,749 | ||
| 2017-12-12 | NELSEN ROBERT Director | Conversion · Series A-1 Preferred Stock | −10,068,749 | 0 | ||
| 2017-12-12 | NELSEN ROBERT Director | Conversion · Series A-2 Preferred Stock | −375,000 | 0 |
Page 52 of 53 · 1,043 trades